证券代码：603059 证券简称：倍加洁 公告编号：2024-028 倍加洁集团股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 5 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 75,704,343 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 75.3661 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事长张文生先生主持，会议的召集、召开及表决方式符合《中华人 民共和国公司法》、《中华人民共和国证券法》、《上市公司股东大会规则》、《上海 证券交易所股票上市规则》及《公司章程》等法律法规及规范性文件的有关规定， (一) 股东大会召开的时间：2024 年 5 月 22 日 (二) 股东大会召开的地点：公司 8 号会议室 (三) 出席会议 ...

股东大会资料 倍加洁集团股份有限公司 PERFECT GROUP CORP.,LTD （江苏省扬州市杭集工业园） 2023 年年度股东大会资料 1 股东大会资料 2023 年年度股东大会会议须知 为了维护广大投资者的合法权益，确保股东大会的正常秩序和议事效率， 根据《中华人民共和国公司法》（以下简称"公司法"）、《上海证券交易所股票 上市规则》及《倍加洁集团股份有限公司章程》（以下简称"公司章程"）等相 关法律、法规及规范性文件，制定本须知，请出席股东大会的全体人员自觉遵守。 1、大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 2、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务必 请出席大会的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场 签到确认参会资格。股东在参会登记时间内没有通过传真或书面信函方式登记 的，不在签到表上登记签到的，或会议正式开始后没有统计在会议公布股权数之 内的股东或代理人，不得参加表决。 3、出席会议的股东（或股东代理人）依法享有发言权、表决权等各项权利， 并履行法定义务和遵守相关规则。大会召开期间，股东事先准备发言的，应当在 办理会议登记手续时 ...

证券代码：603059 证券简称：倍加洁 公告编号：2024-027 倍加洁集团股份有限公司 关于全资子公司对外投资设立子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：倍加洁集团股份有限公司（以下简称"公司"）全资子公 司扬州倍加洁日化有限公司（以下简称"倍加洁日化"）在杭州设立子公司杭州 益亲电子商务有限公司（以下简称"杭州益亲"）。 投资金额：注册资本 600 万元。 特别风险提示: 本次对外投资是基于公司战略规划和业务发展做出的审 慎决策，但仍存在因政策、市场、管理等各方面不确定因素带来的风险，本公司 将采取适当的策略、管理措施加强风险管控，积极防范和应对风险。 一、对外投资概述 （一）基于公司的战略规划和业务发展需要，公司全资子公司倍加洁日化在 杭州设立子公司杭州益亲，本次投资一方面可以借助当地电商资源，进一步拓展 电商销售渠道，及时把握商业机遇，夯实公司主营业务，另一方面，通过在电商 渠道实现品牌创新展示，有助于提升公司品牌的知名度和市场竞争力，从而提升 公司综合竞争力。 ...

23 年及 24Q1 财报点评：24Q1 主业势头向好，外延并购打开成长 天花板 2024 年 04 月 25 日 公司点评 买入/维持 太 平 洋 证 券 股 份 有 限 公 司 证 券 研 究 报 告 公司点评 P2 23 年及 24Q1 财报点评：24Q1 主业势头向好，外延并购打开成长 天花板 风险提示：原材料价格波动风险，市场竞争加剧，自主品牌孵化不及预期 等 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 投资评级说明 1、行业评级 2、公司评级 太平洋研究院 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 重要声明 本报告信息均来源于公开资料，我公司对这些信息的准确性和完整性不作任何保证。负责准备本 报告以及撰写本报告的所有研究分析师或工作人员在此保证，本研究报告中关于任何发行商或证券所 发表的观点均如实反映分析人员的个人观点。报告中的内容和意见仅供参考，并不构成对所述证券买 卖的出价或询价。我公司及其雇员对使用本报告及其内容所引发的任何直接或间接损失概不负责。我 公司或关联机构可能会持有报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些公司提 供或争取提供投资银行业 ...

美容护理/个护用品 Q1 需求恢复业绩迎拐点，期待大健康领域业务表现 | --- | --- | |-------------------------|-------------| | 日期 | 2024/4/25 | | 当前股价 ( 元 ) | 22.93 | | 一年最高最低 ( 元 ) | 26.02/16.42 | | 总市值 ( 亿元 ) | 23.03 | | 流通市值 ( 亿元 ) | 23.03 | | 总股本 ( 亿股 ) | 1.00 | | 流通股本 ( 亿股 ) | 1.00 | | 近 3 个月换手率 (%) | 96.66 | 数据来源：聚源 《业绩符合预期，关注薇美姿股权交 割—公司信息更新报告》-2023.10.25 《牙刷 ODM 龙头，内生外延促长期 持续发展—公司首次覆盖报告》 -2023.9.22 | --- | --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------|-------| | 指标 | 2022A | 2023A | 2024E | 20 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [4][29]. Core Insights - In Q1 2024, the company achieved a revenue of 286 million yuan, representing a year-on-year growth of 28.29%, and a net profit attributable to the parent company of 19 million yuan, which is a significant increase of 164.53% year-on-year [2]. - The company aims for over 20% revenue growth in 2024, with a target profit margin of around 7% for its main business [2]. - The company has successfully acquired a 52% stake in Shan'enkang, which focuses on the entire probiotic industry chain, and expects to achieve net profits of no less than 12 million, 18 million, and 30 million yuan in 2024, 2025, and 2026 respectively [3][29]. Financial Performance - In 2023, the company reported a total revenue of 1.067 billion yuan, a year-on-year increase of 1.58%, while the net profit attributable to the parent company was 93 million yuan, a decrease of 4.93% year-on-year [2][20]. - The gross profit margin for 2023 was 23.19%, down 0.78 percentage points year-on-year, and the net profit margin was 8.67%, down 0.59 percentage points year-on-year [2]. - The company’s revenue from oral care products in 2023 was 722 million yuan, a year-on-year increase of 7.90%, while the revenue from wet wipes was 336 million yuan, a decline of 9.88% year-on-year [28]. Business Development - The company has established strong partnerships with major clients such as Chongqing Dengkang and Medline, and has successfully developed new international brand clients, which are expected to contribute to revenue in the second half of 2024 [28]. - The acquisition of a 16.50% stake in Weimeizi has positioned the company as the largest single shareholder, enhancing synergies in the oral care business [3][29]. Future Projections - The company forecasts net profits of 143 million, 185 million, and 228 million yuan for the years 2024, 2025, and 2026 respectively, with corresponding earnings per share (EPS) of 1.42, 1.84, and 2.27 yuan [29]. - The projected price-to-earnings (P/E) ratios for the next three years are 16, 12, and 10 times [29].

[Table_PageText] 倍加洁|年报点评 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 流动资产 507 469 600 799 986 经营活动现金流 151 155 122 146 163 货币资金 127 70 160 280 391 净利润 97 93 123 159 196 应收及预付 160 205 230 279 310 折旧摊销 73 81 68 71 76 存货 145 160 174 202 244 营运资金变动 7 -8 -54 -59 -77 其他流动资产 76 34 37 37 41 其它 -27 -11 -15 -25 -32 非流动资产 1,079 1,546 1,523 1,493 1,480 投资活动现金流 -82 -495 5 15 -4 长期股权投资 98 934 934 934 934 资本支出 -69 -33 -46 -42 -64 固定资产 462 456 433 402 388 投资变动 -23 -463 0 0 0 在建工程 30 ...

Investment Rating - The report maintains a "Buy" rating for the company [7][10]. Core Views - The company reported a revenue of 1.067 billion yuan in 2023, a year-on-year increase of 1.6%, but a decline in net profit by 4.9% to 93 million yuan. The first quarter of 2024 showed a significant revenue increase of 28.3% year-on-year to 286 million yuan, with net profit rising by 164.5% to 1.9 million yuan [1]. - The company is optimizing its organizational structure, leading to significant cost reduction and efficiency improvements. A new product management department has been established, and the number of new product launches exceeded expectations [2]. - Cash flow has improved, with net operating cash flow reaching 155 million yuan in 2023, a slight increase from the previous year. The company's operational capabilities remain stable, with accounts receivable turnover days decreasing by 3 days [3]. - The company is experiencing growth in its OEM business, with toothbrush and wet wipes showing improved performance. New product categories are also gaining traction, particularly in toothpaste and dental floss [4][5]. - The company holds significant stakes in two subsidiaries, Weimeizi and Shanenkang, which are expected to contribute positively to its financial performance in the coming years [6]. Financial Summary - In 2023, the company achieved a revenue of 1.067 billion yuan, with a projected revenue growth rate of 19.5% for 2024. The net profit for 2024 is expected to be 143 million yuan, reflecting a growth rate of 54.7% [8]. - The company's earnings per share (EPS) for 2024 is projected to be 1.42 yuan, with a price-to-earnings (P/E) ratio of 15.9 times [8]. - The financial indicators show a stable return on equity (ROE) of 7.4% in 2023, with expectations to rise to 10.4% in 2024 [8].

Investment Rating - The investment rating for the company is "Buy" with a target price of 33.36 CNY, maintaining the previous rating of "Buy" [2][6]. Core Views - The company's main business shows a stable upward trend, and external acquisitions open up growth opportunities [2][6]. - The probiotic sector is expected to achieve steady revenue and profit growth [2][6]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 1.067 billion CNY, representing a 1.58% increase year-on-year, and a net profit of 0.93 billion CNY, down 4.93% year-on-year [2][6]. - For Q1 2024, the company reported a revenue of 1.19 billion CNY, up 15.76% year-on-year, with a net profit of 0.19 billion CNY, up 164.53% year-on-year [2][6]. Earnings Forecast - EPS forecasts for 2024, 2025, and 2026 are 1.39 CNY, 1.65 CNY, and 1.91 CNY respectively [2][6]. - The company expects to maintain a stable profit margin with a projected EBIT margin of 10.6% for 2024 [2][6]. Business Outlook - The company is focusing on expanding its product lines, including toothbrushes, dental floss, and wet wipes, which are expected to contribute to revenue growth [2][6]. - The acquisition of Shanenkang is anticipated to enhance the company's revenue and profit contributions through integrated supply chain advantages [2][6]. Market Position - The company has established a strong market presence in the oral care and disposable hygiene products sectors, with a diversified product portfolio [2][6]. - The company is positioned as a leading manufacturer in the domestic market, with significant export capabilities [2][6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance [2]. Core Insights - The company reported a revenue of 1.067 billion yuan in 2023, a year-on-year increase of 1.6%, while the net profit attributable to shareholders was 93 million yuan, down 4.9% year-on-year. The first quarter of 2024 showed significant improvement with a revenue of 286 million yuan, up 28.3% year-on-year, and a net profit of 19 million yuan, up 164.5% year-on-year [7][2]. - The company is positioned well in the oral care sector, benefiting from a shift towards high-quality domestic brands and expanding product lines with existing clients. The introduction of new products is expected to drive future growth [2]. - Profit forecasts have been adjusted upwards, with the 2024 net profit projected at 154 million yuan, 207 million yuan for 2025, and 255 million yuan for 2026, reflecting year-on-year growth rates of 66.5%, 34.5%, and 23.2% respectively [2]. Financial Summary - The company’s total revenue for 2024 is estimated at 1.307 billion yuan, with a year-on-year growth rate of 22.5%. The gross margin is expected to improve, with 2024 projected at 24.6% [16][24]. - The company’s earnings per share (EPS) for 2024 is forecasted to be 1.53 yuan, with a PE ratio of 15 for 2024, decreasing to 9 by 2026 [16][24]. - The company has shown a positive trend in its core business fundamentals, with a significant recovery in order volumes for toothbrushes and a strong growth trajectory in other oral care products [7][2].